CLLS - cellectis.com Forward Price-to-Revenue Multiple

Cellectis S.A. is a French leader in gene editing that attracts top scientists through its unique laboratory infrastructure. The forward P/S multiple on this chart clearly demonstrates valuation volatility, with the metric reaching 2.40. While geopolitical tensions and disruptions in biomaterial logistics are hindering growth, a strategic alliance with AstraZeneca ensures a steady flow of R&D investment.

Cellectis - CLLS Projected Price to Revenue (period 07/04/2022 - 11/13/2026)

cellectis.com - analytical breakdowns and key metrics (CLLS)

- market price and analyst price targets:

Price Chart Cellectis|CLLS - Price Target Chart

- market capitalization statistics:

Market Valuation CLLS|CLLS - Value Adjusted for Debt and Cash

- business book valuation details:

Book Value per Share Cellectis S.A.|CLLS - Book Value of Business|Market Capitalization to Book Value Ratio cellectis.com|CLLS - Company Assets

- debt and solvency information:

- financial results and valuation multiples details:

CLLS - Final Profit|Projected Future Earnings Cellectis S.A.|CLLS - Market Cap to Earnings|Future Price to Earnings Cellectis|CLLS - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple CLLS|CLLS - Operating profit EBITDA|Earnings per share for the last twelve months Cellectis S.A.|CLLS - Earnings per one share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months cellectis.com|CLLS - Earnings per share growth rate in current year|Earnings growth forecast for next year Cellectis S.A.

- revenue and sales proceeds data:

CLLS - Company Sales|Projected Sales Volume Cellectis|CLLS - Price to Sales|Price-to-Projected Revenue Ratio CLLS

Initial company analysis:Cellectis Biotherapeutics (CLLS)

This indicator reflects the market value of Cellectis S.A. (CLLS) relative to expected revenue, allowing for an assessment of the degree of optimism currently priced in regarding future cash flows. By analyzing the business's forward P/S, an investor can compare market expectations with the effectiveness of management's strategy for implementing CAR-T technologies and the quality of their partnerships with pharmaceutical behemoths.

Key competitors

Price-to-Projected Revenue Ratio Legend Biotech Corporation LEGN|Sana Biotechnology Inc - Price-to-Projected Revenue Ratio|AUTL: Forward Price-to-Revenue Multiple|Forward Price to Sales ALLO (Allogene Corp)|RNAC: Forward P/S Multiple|Projected Price to Revenue cariboubio.com CRBU|TIL (Instil Bio) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Genenta GNTA|Price-to-Projected Revenue Ratio Century Therapeutics (IPSC)|jaspertherapeutics.com - Market Cap to Projected Revenue|Forward P/S Multiple SNTI (Senti Biosciences)|Adaptimmune Therapeutics plc (ADAP) - Market Cap to Future Revenue Ratio|CERO: Forward Price-to-Revenue Multiple|Forward Price to Sales TCRT (Alaunos Therapeutics)|ACHL (achillestx.com) - Forward Price-to-Revenue Multiple|CRGX: Price to Expected Revenue Ratio|PSTX (Poseida Therapeutics) - Forward P/S Multiple|TSVT: Forward Price to Sales|Forward P/S Multiple GRCL